Unlike the EGFR kinase-activating mutations that occur mainly in NSCLC patients, wild-type EGFR protein is commonly over-expressed in many types of solid cancers and is often associated with negative prognosis (31–47), i.e., over-expression of wild-type EGFR is a more common phenomenon than EGFR mutations in solid cancers and promotes disease progression. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.